The global oncology biosimilars market is expected to expand at a compound annual growth rate (CAGR) of 29.87% over the period 2013-2018, according to a new report added to the offering of Research and Markets.
Biosimilar medicines have a mechanism of action that is similar to that of the original biological medicines. Though biosimilars have many similarities to the innovator product, they are not an exact copy of the reference biopharmaceutical product. Currently, biosimilars are being incorporated into oncology treatment practices. The biosimilars used in oncology in the supportive care setting are known as oncology biosimilars.
The development and introduction of biosimilars, according to the report, will be dominated by India’s Biocon and Dr Reddy’s, South Korea’s Celltrion, US firms Hospira and Mylan, and Sandoz, the generics subsidiary of Swiss drug major Novartis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze